Drug Type Small molecule drug |
Synonyms NRDN201 |
Target |
Action agonists |
Mechanism Ca2+-ATPases agonists |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | United States | 10 Dec 2022 | |
Parkinson Disease | Preclinical | United States | 10 Feb 2022 |